<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03972878</url>
  </required_header>
  <id_info>
    <org_study_id>FP-1.0</org_study_id>
    <nct_id>NCT03972878</nct_id>
  </id_info>
  <brief_title>Foodprint 1.0: Physiological Acute Responses After Consumption of Confectionary Products</brief_title>
  <acronym>FP1</acronym>
  <official_title>Foodprint 1.0: Metabolic, Hormonal, Inflammatory and Oxidative Post-prandial Responses After Consumption of Confectionary Products</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Parma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Parma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The composition of a food or a meal consumed plays an important role in the rate of&#xD;
      postprandial endocrine and metabolic response, especially if high in fats, sugars and total&#xD;
      energy content and a reduction in its entity is related to beneficial effects towards the&#xD;
      prevention of several chronical diseases. The physiological postprandial response depends on&#xD;
      several factors, both intrinsic, such as natural characteristic of food, and extrinsic, such&#xD;
      as the way in which food is processed. This study aims at investigating postprandial&#xD;
      hormonal, metabolic, oxidative stress, inflammation and endotoxaemia responses after the&#xD;
      consumption of different commercial confectionary products made with different reformulation&#xD;
      (ingredients and/or processing techniques).The principal scope of the study is to evaluate&#xD;
      the impact of the reformulation of different snacks on postprandial responses. The&#xD;
      investigators therefore designed a randomized controlled crossover trial, in which 15 healthy&#xD;
      volunteers will consume different isocaloric confectionary products (snacks) and their&#xD;
      related reformulation (total products number = 6) and a reference snack. Venous blood samples&#xD;
      will be collected until 4-h after meal consumption. In order to evaluate postprandial&#xD;
      hormonal, metabolic, oxidative stress, inflammation and endotoxaemia responses several&#xD;
      markers will be evaluate:&#xD;
&#xD;
        -  metabolic substrates: glucose; Triglycerides and NEFA;&#xD;
&#xD;
        -  hormones: insulin; c-peptide; GLP-1, GIP, leptin, ghrelin, PYY;&#xD;
&#xD;
        -  markers of inflammation: IL-6, IL-8, IL-10, IL-17, TNF-α, hsCRP, MCP-1;&#xD;
&#xD;
        -  markers of oxidative stress and antioxidant capacity: GSH, FRAP;&#xD;
&#xD;
        -  endotoxaemia: lipopolysaccharides (LPS).&#xD;
&#xD;
      These results will contribute to a detailed evaluation of the effects of reformulation on&#xD;
      physiological events after meal consumption, leading to clarify if these variations in&#xD;
      ingredients and/or processing techniques can modify postprandial responses, making them more&#xD;
      similar to those originated from the reference snack.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Meal consumption, especially if high in fats, sugars and total energy content, leads to a&#xD;
      transient rise in blood glucose and lipids. The extent of glycemic and lipidemic postprandial&#xD;
      responses have been linked to the progression of cardiovascular and other chronic&#xD;
      degenerative diseases, such as type 2 diabetes and Alzheimer through a substantial increase&#xD;
      in oxidative stress, systemic inflammation, and endothelial dysfunction. In addition, some&#xD;
      studies have shown that consuming a high fat meal is associated with a postprandial increase&#xD;
      in plasma and serum endotoxin concentrations in humans. LPS, lipopolysaccharide, is&#xD;
      considered a major predisposing factor for inflammation-associated diseases such as&#xD;
      atherosclerosis, sepsis and obesity. Therefore, following a correct dietary model may be&#xD;
      beneficial in order to limit postprandial excursion and to modulate hormonal responses&#xD;
      involved in satiety.&#xD;
&#xD;
      The physiological postprandial response depends on several factors, both intrinsic, such as&#xD;
      natural characteristic of food, and extrinsic, such as the way in which food is processed.&#xD;
      Thus, the present study aims at evaluating if the reformulation of some commercial&#xD;
      confectionery products can lead to an improvement of the nutritional profile, through a&#xD;
      decrease of postprandial metabolic and hormonal, oxidative stress, inflammation and&#xD;
      endotoxaemia responses in comparison with commercial confectionery products (snacks).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 22, 2019</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The study is a cross-over, randomized intervention trial. Each subject consumed in a randomly order seven foods test with a one-week wash out between different treatments. The portion size of each foods test was calculated in order to provide the same calories.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IAUC postprandial blood glucose</measure>
    <time_frame>0 (fasting), 15, 30, 45, 60, 90, 120, 180, 240 minutes</time_frame>
    <description>Incremental area under the curve of blood glucose postprandial response (IAUC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postprandial response for blood glucose</measure>
    <time_frame>0 (fasting), 15, 30, 45, 60, 90, 120, 180, 240 minutes</time_frame>
    <description>incremental blood glucose concentration at each timepoint of the curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IAUC postprandial blood hormones (insulin, c-peptide, ghrelin, Glucagon-like peptide 1 (GLP-1), Gastric inhibitory peptide (GIP), peptide YY (PYY), leptin)</measure>
    <time_frame>0 (fasting), 15, 30, 45, 60, 90, 120, 180, 240 minutes</time_frame>
    <description>Incremental area under the curve for blood insulin postprandial response (IAUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial response for blood hormones (insulin, c-peptide, ghrelin, Glucagon-like peptide 1 (GLP-1), Gastric inhibitory peptide (GIP), peptide YY (PYY), leptin)</measure>
    <time_frame>0 (fasting), 15, 30, 45, 60, 90, 120, 180, 240 minutes</time_frame>
    <description>incremental blood insulin concentration at each timepoint of the curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IAUC postprandial blood lipids triglycerides (TAG) and non esterified fatty acid (NEFA)</measure>
    <time_frame>0 (fasting), 30, 60, 90, 120, 180, 240 minutes</time_frame>
    <description>Incremental area under the curve for blood TAG and NEFA postprandial response (IAUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial response for blood lipids triglycerides (TAG) and non esterified fatty acid (NEFA)</measure>
    <time_frame>0 (fasting), 30, 60, 90, 120, 180, 240 minutes</time_frame>
    <description>incremental blood TAG and NEFA concentration at each timepoint of the curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IAUC postprandial blood inflammatory markers (IL-6, IL-8, IL-10, IL-17, TNF-α, hsCRP, MCP-1)</measure>
    <time_frame>0 (fasting), 60, 90, 120, 180, 240 minutes</time_frame>
    <description>Incremental area under the curve for blood inflammatory markers (IL-6, IL-8, IL-10, IL-17, TNF-α, hsCRP, MCP-1) postprandial response (IAUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial response for blood inflammatory markers (IL-6, IL-8, IL-10, IL-17, TNF-α, hsCRP, MCP-1)</measure>
    <time_frame>0 (fasting), 60, 90, 120, 180, 240 minutes</time_frame>
    <description>incremental blood inflammatory markers (IL-6, IL-8, IL-10, IL-17, TNF-α, hsCRP, MCP-1) concentration at each timepoint of the curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IAUC postprandial blood oxidative stress related markers glutathione (GSH) and antioxidant capacity (Ferric ion reducing antioxidant power (FRAP))</measure>
    <time_frame>0 (fasting), 60, 90, 120, 180, 240 minutes</time_frame>
    <description>Incremental area under the curve for blood oxidative stress related markers glutathione (GSH) and antioxidant capacity (Ferric ion reducing antioxidant power (FRAP))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial response for blood oxidative stress related markers glutathione (GSH) and antioxidant capacity (Ferric ion reducing antioxidant power (FRAP))</measure>
    <time_frame>0 (fasting), 60, 90, 120, 180, 240 minutes</time_frame>
    <description>incremental blood oxidative stress related markers glutathione (GSH) and antioxidant capacity (Ferric ion reducing antioxidant power (FRAP)) concentration at each timepoint of the curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IAUC postprandial blood endotoxemia (Lipopolysaccharides (LPS))</measure>
    <time_frame>0 (fasting), 60, 90, 120, 180, 240 minutes</time_frame>
    <description>Incremental area under the curve for LPS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial response for blood LPS</measure>
    <time_frame>0 (fasting), 60, 90, 120, 180, 240 minutes</time_frame>
    <description>incremental blood LPS concentration at each timepoint of the curve</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Postprandial satiety using a 100mm visual analog scale</measure>
    <time_frame>0 (fasting), 15, 30, 60, 120, 240 minutes</time_frame>
    <description>Differences in subject-rated satiety using a 100mm visual analog scale (centimeter) Range 0-10 centimeter. Higher are the values of satiety in each timepoints better is the product.</description>
  </other_outcome>
  <other_outcome>
    <measure>Palatability</measure>
    <time_frame>12 minutes (after consumption)</time_frame>
    <description>Palatability using a 100mm visual analog scale (centimeter). Range 0-10 centimeter. Higher is the value of palatability better is the product.</description>
  </other_outcome>
  <other_outcome>
    <measure>Postprandial gastrointestinal symptoms using a 100mm visual analog scale</measure>
    <time_frame>0 (fasting), 15, 30, 60, 120, 240 minutes</time_frame>
    <description>gastrointestinal symptoms using a 100mm visual analog scale (centimeter). range 0-10 centimeter. Lower are the values of gastrointestinal symptoms better is the product.</description>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Glucose, High Blood</condition>
  <condition>Inflammatory Response</condition>
  <condition>Oxidative Stress</condition>
  <condition>Endotoxemia</condition>
  <arm_group>
    <arm_group_label>control snack</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>control snack</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>control spreadable cream</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cream version 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>control spreadable cream, version 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cream version 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>control spreadable cream, version 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cream version 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>control spreadable cream, version 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control chocolate bar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>control chocolate bar</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chocolate bar version 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>control chocolate bar version 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control snack</intervention_name>
    <description>dry fruit snack (200 kcal) + 250 ml water</description>
    <arm_group_label>control snack</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control cream</intervention_name>
    <description>commercial spreadable cocoa and hazelnut cream (200 kcal)+ 250 ml water</description>
    <arm_group_label>control cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cream version 1</intervention_name>
    <description>commercial spreadable cocoa and hazelnut cream (200 kcal), version 1+ 250 ml water</description>
    <arm_group_label>cream version 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cream version 2</intervention_name>
    <description>commercial spreadable cocoa and hazelnut cream (200 kcal), version 2+ 250 ml water</description>
    <arm_group_label>cream version 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cream version 3</intervention_name>
    <description>commercial spreadable cocoa and hazelnut cream (200 kcal), version 3+ 250 ml water</description>
    <arm_group_label>cream version 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control chocolate bar</intervention_name>
    <description>commercial chocolate bar (200 kcal)+ 250 ml water</description>
    <arm_group_label>control chocolate bar</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>chocolate bar version 1</intervention_name>
    <description>commercial chocolate bar (200 kcal), version 1+ 250 ml water</description>
    <arm_group_label>chocolate bar version 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Healthy male and female adult subjects&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI &gt; 30 kg/m2&#xD;
&#xD;
          -  Metabolic disorders (diabetes, hypertension, dyslipidemia, glucidic intolerance)&#xD;
&#xD;
          -  Chronic drug therapies for any pathologies (including psychiatric diseases)&#xD;
&#xD;
          -  Dietary supplements affecting metabolism of glucose and lipid&#xD;
&#xD;
          -  Celiac disease&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Lactose intolerance&#xD;
&#xD;
          -  Food allergies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Parma</name>
      <address>
        <city>Parma</city>
        <zip>43125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Emerson SR, Kurti SP, Harms CA, Haub MD, Melgarejo T, Logan C, Rosenkranz SK. Magnitude and Timing of the Postprandial Inflammatory Response to a High-Fat Meal in Healthy Adults: A Systematic Review. Adv Nutr. 2017 Mar 15;8(2):213-225. doi: 10.3945/an.116.014431. Print 2017 Mar. Review.</citation>
    <PMID>28298267</PMID>
  </reference>
  <reference>
    <citation>Erridge C, Attina T, Spickett CM, Webb DJ. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr. 2007 Nov;86(5):1286-92.</citation>
    <PMID>17991637</PMID>
  </reference>
  <reference>
    <citation>Herieka M, Erridge C. High-fat meal induced postprandial inflammation. Mol Nutr Food Res. 2014 Jan;58(1):136-46. doi: 10.1002/mnfr.201300104. Epub 2013 Jul 12. Review.</citation>
    <PMID>23847095</PMID>
  </reference>
  <reference>
    <citation>O'Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol. 2007 Sep 1;100(5):899-904. Epub 2007 Jun 26. Review.</citation>
    <PMID>17719342</PMID>
  </reference>
  <reference>
    <citation>Treib J, Haass A, Kiessig ST, Woessner R, Grauer MT, Schimrigk K. Tick-borne encephalitis diagnosis in patients with inflammatory changes in the cerebrospinal fluid in a region with very low prevalence. Infection. 1996 Sep-Oct;24(5):400-2.</citation>
    <PMID>8923057</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Parma</investigator_affiliation>
    <investigator_full_name>Daniele Del Rio</investigator_full_name>
    <investigator_title>Professor of Nutrition at Department of Veterinary Science, University of Parma</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endotoxemia</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

